Drug intelligence / Profile preview

ISM4824

Development stage: Preclinical
Lead developer: InSilico Medicine
Modality: Small Molecules

Overview

ISM4824 is an AI-designed preclinical small molecule developed by Insilico Medicine. It is being developed against an undisclosed oncology target. Insilico Medicine licensed exclusive global rights for ISM4824, excluding China, to Menarini Group for further development. Insilico Medicine retains rights in China and co-development options.

Beyond the preview

Go deeper on ISM4824.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISM4824.

Explore the full profile